U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

(Reuters) -U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Robert F. Kennedy Jr. petitioned the F.D.A. to revoke authorization of the shots at a time when they were in high demand and ...